文献速递免疫规划卫生政策与健康促进

马来西亚mRNA与灭活COVID-19疫苗接种、加强针及突破性感染后免疫应答的纵向动态

Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
PubMed 文献 · Vaccine · 2025-08-27

马来西亚因疫苗短缺采用BNT162b2、CoronaVac和ChAdOx1 nCoV-19异源加强策略,本研究评估健康人基础免疫和加强针后的体液应答,以及健康人和肾移植受者加强针后长达两年的杂交免疫。BNT162b2抗S抗体应答强于CoronaVac,mRNA方案加强后抗体维持6个月,突破性感染后抗N抗体快速升高但3个月内回落,肾移植受者T细胞应答下降。

要点

  • 第二剂后3个月,BNT162b2抗S抗体为3.0 log U/mL,高于CoronaVac的1.6 log U/mL。
  • mRNA方案加强后抗S抗体达3.6-3.7 log U/mL并维持6个月,CoronaVac同源加强为2.8 log U/mL。
  • 突破性感染后抗N抗体快速升高,3个月内回落至感染前水平。

核心结论

  • BNT162b2基础免疫的抗S抗体应答强于CoronaVac,mRNA加强方案可提升并维持抗S抗体至6个月。
  • 突破性感染后抗N抗体快速升高但3个月内回落,加强针后两年感染时健康人T细胞应答增加而肾移植受者下降。
  • 作者认为需全面免疫评估以指导预防策略,尤其对免疫受损人群。

研究设计与样本

  • 研究评估健康人基础免疫和加强针后的体液应答,以及健康人和肾移植受者加强针后长达两年的杂交免疫。
  • 马来西亚因疫苗短缺采用BNT162b2、CoronaVac和ChAdOx1 nCoV-19异源加强策略。

主要发现

  • 第二剂后3个月,BNT162b2抗S抗体为3.0 log U/mL,CoronaVac为1.6 log U/mL。
  • CoronaVac受者抗N抗体血清阳转率为50.3%。
  • BNT162b2/BNT162b2、ChAdOx1 nCoV-19/BNT162b2和CoronaVac/BNT162b2加强后抗S抗体为3.6-3.7 log U/mL并维持6个月,CoronaVac/CoronaVac加强为2.8 log U/mL。
  • 突破性感染后抗N抗体快速升高,3个月内回落至感染前水平。
  • 加强针后两年感染的个体中,健康参与者T细胞应答增加,肾移植受者尽管抗体应答强但T细胞应答下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During the COVID-19 pandemic, Malaysia adopted heterologous vaccine booster strategies using BNT162b2 (Pfizer), CoronaVac (Sinovac) and ChAdOx1 nCoV-19 (AstraZeneca) due to vaccine shortages. However, longitudinal data on immune durability and breakthrough infections, especially in immunocompromised groups, remain limited. This study evaluates humoral response in healthy individuals after primary vaccine series and booster dose, and assesses long-term hybrid immunity up to two years post-booster in both healthy individuals and immunocompromised kidney transplant recipients (KTRs). BNT162b2 vaccine elicited a stronger anti-spike (anti-S) antibody response (3.0 log U/mL) compared to CoronaVac (1.6 log U/mL) at 3 months post-second dose. Anti-nucleocapsid (anti-N) antibody seroconversion was 50.3 % in CoronaVac recipients, suggesting limited humoral responses against N protein. Booster vaccination with homologous or heterologous mRNA-based regimens (BNT162b2/BNT162b2, ChAdOx1 nCoV-19/BNT162b2, and CoronaVac/BNT162b2) further enhanced anti-S antibody responses (3.6-3.7 log U/mL) for up to 6 months, whereas homologous CoronaVac/CoronaVac boosters yielded lower antibody levels (2.8 log U/mL). Breakthrough infections triggered a rapid rise in anti-N antibody, followed by a decline back to pre-infection levels within 3 months. In individuals infected two years after booster vaccination, T cell responses increased in healthy participants but declined in KTRs despite strong antibody responses, suggesting immunosuppressive therapy may impair T cell activation. These findings highlight the need for comprehensive immune assessments to guide preventive strategies, especially for immunocompromised populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fu JYL, Syed Omar SF, Rajasuriar R, et al. Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia. Vaccine. 2025. PMID: 40876143. doi:10.1016/j.vaccine.2025.127657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。